Immune-Related Adverse Events: Findings From a Population-Based Study

Immune checkpoint inhibitors (ICIs) are effective for several tumor entities but cause immune-related adverse events (irAEs). These side effects may affect any organ and often lead to ICI discontinuation, hospitalization, long-term complications, or sequelae. To assess the burden of irAEs, this longitudinal observational study analyzed their incidence and the frequency of related hospitalizations using anonymized health claims data from a payer database covering 5.8 million insured individuals in Germany. Patients with hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), renal cancer, urothelial cancer, or skin cancer who started ICI therapy between 2017 and 2020 were selected using ICD-10 GM (International Statistical Classification of Diseases, German Modification) codes. The incidence of irAEs and related hospitalizations within 6 months was assessed using predefined ICD-10 codes in both inpatient and outpatient settings. A total of 6350 patients (mean age: 66.8 y) with NSCLC (n=4797), skin cancer (n=1266), HCC (n=1249), renal (n=1183), or urothelial cancer (n=656) initiated ICI therapy between 2017 and 2020. The incidence of any new-onset irAE was 31.4% (95% CI: 30.3%-32.6%). New-onset respiratory irAEs were the most common [11.7% (95% CI: 11.0%-12.5%)], followed by gastrointestinal irAEs (7.8%; 95% CI: 7.1%-8.5%). Skin cancer patients most frequently developed gastrointestinal irAEs, while other tumor types showed more respiratory irAEs. Using an inclusive definition that also captures exacerbations of pre-existing conditions, nearly half of patients experienced at least one hospitalization with an irAE recorded as the main discharge diagnosis within 6 months after ICI initiation. These findings underscore the importance of monitoring and management to reduce patient and healthcare impact.

Authors

Institutions

Publication Details

Journal
Journal of Immunotherapy
Published
2026-11-12
DOI
https://doi.org/10.1097/cji.0000000000000629
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune-Related Adverse Events: Findings From a Population-Based Study

Sina Theis, Lucie Heinzerling, Tobias Vogelmann, I. Seemann et al.
Journal of Immunotherapy
Cancer Immunotherapy and Biomarkers
article

Immune-Related Adverse Events: Findings From a Population-Based Study

Sina Theis, Lucie Heinzerling, Tobias Vogelmann, I. Seemann, Andy Ingram
article en

Abstract

Immune checkpoint inhibitors (ICIs) are effective for several tumor entities but cause immune-related adverse events (irAEs). These side effects may affect any organ and often lead to ICI discontinuation, hospitalization, long-term complications, or sequelae. To assess the burden of irAEs, this longitudinal observational study analyzed their incidence and the frequency of related hospitalizations using anonymized health claims data from a payer database covering 5.8 million insured individuals in Germany. Patients with hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), renal cancer, urothelial cancer, or skin cancer who started ICI therapy between 2017 and 2020 were selected using ICD-10 GM (International Statistical Classification of Diseases, German Modification) codes. The incidence of irAEs and related hospitalizations within 6 months was assessed using predefined ICD-10 codes in both inpatient and outpatient settings. A total of 6350 patients (mean age: 66.8 y) with NSCLC (n=4797), skin cancer (n=1266), HCC (n=1249), renal (n=1183), or urothelial cancer (n=656) initiated ICI therapy between 2017 and 2020. The incidence of any new-onset irAE was 31.4% (95% CI: 30.3%-32.6%). New-onset respiratory irAEs were the most common [11.7% (95% CI: 11.0%-12.5%)], followed by gastrointestinal irAEs (7.8%; 95% CI: 7.1%-8.5%). Skin cancer patients most frequently developed gastrointestinal irAEs, while other tumor types showed more respiratory irAEs. Using an inclusive definition that also captures exacerbations of pre-existing conditions, nearly half of patients experienced at least one hospitalization with an irAE recorded as the main discharge diagnosis within 6 months after ICI initiation. These findings underscore the importance of monitoring and management to reduce patient and healthcare impact.

Journal of Immunotherapy
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Universitätsklinikum Erlangen (DE), Ludwig-Maximilians-Universität München (DE)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon